ArticleEuropean journal of nuclear medicine and molecular imaging2024
Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles.
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Imaging of MASLD: clinical standards and novel methods.Diabetologia · 2026Review
- Engineering Anti-MMP-9 Peptide-Modified Nanoparticles for Precision MRI Diagnosis of Endometriosis.Molecular imaging and biology · 2026Article
- Molecular Imaging Probes for Early Detection and Staging of Liver Fibrosis.Chemical & biomedical imaging · 2025Review
- Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease.Asian journal of pharmaceutical sciences · 2025Review
- Biomedical Application Prospects of Gadolinium Oxide Nanoparticles for Regenerative Medicine.Pharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionAccurate diagnosis of liver fibrosis is crucial for preventing cirrhosis and liver tumors. Liver fibrosis is driven by activated hepatic stellate cells (HSCs) with elevated CD44 expression. We developed hyaluronic acid (HA)-coated gadolinium-based nanoprobes to specifically target CD44 for diagnosing liver fibrosis using T1-weighted magnetic resonance imaging (MRI). MATERIALS AND
methodsNaGdF
resultsNaGdF
conclusionsNaGdF
Indexed as
Identifiers
39231880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.